MG
FLNA

Mather Group’s Filana Therapeutics FLNA Stock Holding History

Mather Group’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298 Hold
250
– – ﹤0.01% 1855
2026
Q1 		$423 Buy
+250
New +$515 ﹤0.01% 1812
2025
Q4 		– Sell
-250
Closed -$728 – 1460
2025
Q3 		$728 Buy
+250
New +$575 ﹤0.01% 1601
2025
Q2 		– Sell
-250
Closed -$375 – 1507
2025
Q1 		$375 Hold
250
– – ﹤0.01% 1704
2024
Q4 		$590 Hold
250
– – ﹤0.01% 1645
2024
Q3 		$7.36K Hold
250
– – ﹤0.01% 1230
2024
Q2 		$5.07K Hold
250
– – ﹤0.01% 1617
2024
Q1 		$5.63K Buy
+250
New +$5.76K ﹤0.01% 1336

Other funds holding FLNA

AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
JIC
Johnson Investment Counsel Cincinnati, Ohio $13.7B AUM 21.52% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
SIC
Salem Investment Counselors Winston Salem, North Carolina $4.03B AUM 61.49% 1-Year Est. Return
SWA
SOA Wealth Advisors New York $595M AUM 25.98% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return

Mather Group's FLNA Position: Q2 2026 in Review

Mather Group held its Filana Therapeutics (FLNA) position steady in Q2 2026 at 250 shares worth $298. The position accounts for ﹤0.01% of the portfolio, ranked #1855.

Mather Group first reported a position in FLNA in Q1 2024 and has held it in 8 quarters since. The position peaked at $7.36K in Q3 2024. 15 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • Mather Group held 250 shares of Filana Therapeutics worth $298 as of Q2 2026.
  • Mather Group left its Filana Therapeutics share count unchanged in Q2 2026.
  • Filana Therapeutics made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1855 holding.
  • Mather Group first reported a position in Filana Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Mather Group's Filana Therapeutics position peaked at $7.36K in Q3 2024.
  • 15 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.